Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

@inproceedings{Herwaarden2015DiseaseAG,
  title={Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial },
  author={Noortje van Herwaarden and Aatke van der Maas and M J M Minten and Frank H. J. van den Hoogen and Wietske Kievit and Ronald van Vollenhoven and Johannes W J Bijlsma Bijlsma and Bart J. F. van den Bemt and Alfons den Broeder},
  booktitle={BMJ},
  year={2015}
}
OBJECTIVE To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care. DESIGN Randomised controlled, open label, non-inferiority strategy trial. SETTING Two rheumatology outpatient clinics in the Netherlands, from December 2011 to May 2014. PARTICIPANTS 180 patients with rheumatoid arthritis and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 39 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…